Max Healthcare share price falls 5% in 2 days on Q4 results: Should you sell or hold?
₹790 on the NSE, the Max Healthcare share price is down more than 10% from 52-week highs seen in February.Analysts remain positive on growth being fueled by expansions. Analysts at Jefferies India Private Ltd have maintained Buy ratings on Max Healthcare post Q4.
Their Q4 review report said that after In-line 4Q, there is bullish outlook for FY26. They have target price of ₹940 for Max Healthcare share price, which indicates around 17% upsideAnalysts at Prabhudas Lilladher also said that the results were in line and growth is on track.
Their target price stands at ₹925.Analysts at Kotak Institutional Equities though also see strong ebitda growth to be fueled by brownfield expansions, nevertheless say that the same is factored in the share pricesAbhay Soi, Chairman and Managing Director, Max Healthcare Institute post Q4 Results said that “We have consummated two long drawn inorganic deals during the quarter. These transactions add significant capacity going forth and allow for additional brownfield opportunities in the fast growing markets" Also Read- Market Cap of NSE-listed companies surges to $5 trillion from $4 trillion in just 6 monthsMoving forward the growth is likely to be driven by acquired capacities and Brownfield expansions, The 300 bed capacity will be added in early June.
There is going to be 100 bed expansions in Lucknow by December'2024, and there after plenty of capex lined up to fuel growth including expansions at Nanavati Max Hospital ,200 beds to added in Mohali, 300 beds in Saket, New Delhi. All these brownfield expansions will fuel explosive growth over next few years said Soi.
Read more on livemint.com
